RT Journal Article
T1 Effectiveness and Safety of High-Dose Dual Therapy: Results of the European Registry on the Management of Helicobacterpylori Infection (Hp-EuReg).
A1 Fernández-Salazar, Luis
A1 Campillo, Ana
A1 Rodrigo, Luis
A1 Pérez-Aisa, Ángeles
A1 González-Santiago, Jesús M
A1 Segarra Ortega, Xavier
A1 Denkovski, Maja
A1 Brglez Jurecic, Natasa
A1 Bujanda, Luis
A1 Gómez Rodríguez, Blas José
A1 Ortuño, Juan
A1 Georgopoulos, Sotirios
A1 Jonaitis, Laimas
A1 Puig, Ignasi
A1 Nyssen, Olga P
A1 Megraud, Francis
A1 O'Morain, Colm
A1 Gisbert, Javier P
K1 Helicobacter pylori
K1 amoxicillin
K1 effectiveness
K1 eradication
K1 high-dose
K1 registry
K1 rescue treatment
K1 therapy
AB Randomized clinical trials and meta-analyses, primarily from Asian countries, have reported good effectiveness with high-dose dual therapy (HDDT) including a proton pump inhibitor (PPI) and amoxicillin when prescribed as H. pylori first-line or rescue treatment. However, combining amoxicillin with PPIs in the 1990s in several European countries yielded suboptimal results. An international, multicenter, prospective non-interventional Registry (Hp-EuReg) aimed to evaluate the decisions and outcomes of H. pylori management by European gastroenterologists. All infected adult cases treated with HDDT were registered at e-CRF AEG-REDCap platform until June 2021. Sixty patients were prescribed with HDDT (98% compliance), 19 of them received a first-line therapy and 41 a rescue treatment (second- to sixth-line). Overall HDDT effectiveness was 52% (per-protocol) and 51% (modified intention-to-treat). First-line and rescue treatment lines were equally effective, but the effectiveness was worse when patients had previously received metronidazole, tetracycline, or rifabutin. Adding bismuth to HDDT in rescue treatment did not yield better results. The incidence of adverse events was 30%, diarrhea being the most common (20% of patients); no serious adverse events were reported. Although HDDT is safe and has good compliance, it is not a good option in European first-line or rescue H. pylori treatment, even when adding bismuth.
SN 2077-0383
YR 2022
FD 2022-06-20
LK http://hdl.handle.net/10668/21300
UL http://hdl.handle.net/10668/21300
LA en
DS RISalud
RD Apr 4, 2025